372 related articles for article (PubMed ID: 36791198)
1. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E; Gardet C; Chuvin N; Depil S
Sci Adv; 2023 Feb; 9(7):eadf3700. PubMed ID: 36791198
[TBL] [Abstract][Full Text] [Related]
2. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
3. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
D'Ippolito E; Wagner KI; Busch DH
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171940
[TBL] [Abstract][Full Text] [Related]
4. T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.
Hossain NM; Chapuis AG; Walter RB
Curr Hematol Malig Rep; 2016 Aug; 11(4):311-7. PubMed ID: 27095318
[TBL] [Abstract][Full Text] [Related]
5. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy.
Yang D; Duan Z; Yuan P; Ding C; Dai X; Chen G; Wu D
Biochem Biophys Res Commun; 2023 Dec; 687():149209. PubMed ID: 37944471
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
7. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
Shafer P; Kelly LM; Hoyos V
Front Immunol; 2022; 13():835762. PubMed ID: 35309357
[TBL] [Abstract][Full Text] [Related]
8. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.
Shao W; Yao Y; Yang L; Li X; Ge T; Zheng Y; Zhu Q; Ge S; Gu X; Jia R; Song X; Zhuang A
Exp Hematol Oncol; 2024 Apr; 13(1):37. PubMed ID: 38570883
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
10. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
12. TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets R; Donnadieu E; Chouaib S; Coukos G
Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
[TBL] [Abstract][Full Text] [Related]
13. Evolution of CD8
Sun Y; Li F; Sonnemann H; Jackson KR; Talukder AH; Katailiha AS; Lizee G
Cells; 2021 Sep; 10(9):. PubMed ID: 34572028
[TBL] [Abstract][Full Text] [Related]
14. TCR gene-engineered cell therapy for solid tumors.
Tan E; Gakhar N; Kirtane K
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101285. PubMed ID: 34625228
[TBL] [Abstract][Full Text] [Related]
15. [T cell-based immunotherapies in solid tumors].
Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancers through TCR-peptide/MHC interactions.
He Q; Jiang X; Zhou X; Weng J
J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
[TBL] [Abstract][Full Text] [Related]
17. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
18. The recent advancement of TCR-T cell therapies for cancer treatment.
Zhao X; Shao S; Hu L
Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
[TBL] [Abstract][Full Text] [Related]
19. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
20. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]